

IPO Report

Choice

“Subscribe for Long Term” to Corona Remedies Ltd.

Strong growth momentum with healthy margins, but valuation is fully priced.



Salient features of the IPO:

- **Corona Remedies Ltd.** (CRL), Incorporated on August 27, 2004, is an India-focused branded pharmaceutical formulation company engaged in developing, manufacturing, and marketing products across women's healthcare, cardio-diabeto, pain management, urology, and other therapeutic areas. The company ranks as the second fastest-growing player among the top 30 companies in the Indian Pharmaceutical Market (IPM) in terms of domestic sales between MAT June 2022 and MAT June 2025.
- CRL has also demonstrated strong product innovation. Since June 2022, it has recorded a higher share of new product launches with sales exceeding Rs. 5cr in MAT June 2025, accounting for 14.43%, compared with 11.40% for the top 30 pharmaceutical companies in the IPM and 5.60% for the overall IPM.
- This public issue is a solely comprise of OFS (Rs. 655.37cr). The company will not receive any proceeds from the OFS portion.

Key competitive strengths:

- Second fastest growing company within the top 30 pharmaceutical companies in the Indian pharmaceutical market
- Capabilities of building a diversified portfolio, including “engine” brands, in the targeted therapy areas
- Pan-India sales network and marketing strategy focused on the “middle of the pyramid” target market
- Quality and current Good Manufacturing Practices-focused manufacturing facilities, with strong research and development capabilities
- Qualified, experienced and entrepreneurial management team supported by marquee investors

Business strategy:

- Further increase the market share within the domestic Indian pharmaceutical market
- Grow the product portfolio with a focus on long product life cycles and progression
- Expand into other therapeutic areas with significant growth potential and deepen the presence in existing therapeutic areas
- Execute strategic acquisitions and establish in-licensing agreements
- Expand the sales in select overseas markets with a focused approach

Risk and concerns:

- General slowdown in the global economic
- Operates in a regulated environment requiring approvals
- Depends partly on third-party manufacturers (37.3% of revenue)
- Exposure to government price controls may impact operations
- Competition

Valuation Overview and IPO Rating

At the upper end of the price band, CRL is valued at a P/E multiple of 43.5x (based on FY25 EPS of Rs. 24.4) and an EV/Sales multiple of 5.5x, which appears fully priced relative to its peers. The company has demonstrated consistent revenue and profit growth, supported by healthy margins. Around 70% of its revenue is derived from chronic therapies, which are typically high-margin and exhibit strong prescription stickiness. CRL primarily focuses on chronic segments such as women's healthcare, cardiology, and diabetes, offering long-term growth visibility.

Recent acquisitions have strengthened its presence in key chronic segments and improved growth visibility. CRL's IPM ranking has improved from 37th to 29th, reflecting rising scale and competitiveness. While valuations appear fully priced, the company's sustainable business model and long-term growth prospects support a “Subscribe for Long Term” rating for this issue.

Issue details

Price band	Rs. 1,008 - 1,062 per share
Face value	Rs. 10
Shares for fresh issue	Nil
Shares for OFS	0.617 - 0.650cr shares
Fresh issue size	Nil
OFS issue size	Rs. 655.37cr
Total issue size	0.617 - 0.650cr shares (Rs. 655.37cr)
Employee Reservation	0.006cr shares (Rs. 5.85cr)
Net issue size	0.611 - 0.644cr shares (Rs. 649.52cr)
Bidding date	08 th Dec. - 10 th Dec. 2025
Implied MCAP at higher price band	Rs. 6,495.20cr
Implied enterprise value at higher price band	Rs. 6,554.66cr
Book running lead manager	JM Financial Ltd., IIFL Capital Services Ltd., and Kotak Mahindra Capital Company Ltd.
Registrar	Bigshare Services Pvt. Ltd.
Sector	Pharmaceuticals
Promoters	Dr. Kirtikumar Laxmidas Mehta, Niravkumar Kirtikumar Mehta and Ankur Kirtikumar Mehta

Category	Percent of issue (%)	Number of shares
QIB portion	50%	0.306 - 3.22cr shares
Non institutional portion (Big)	10%	0.061 - 0.064cr shares
Non institutional portion (Small)	5%	0.031 - 0.032cr shares
Retail portion	35%	0.214 - 0.226cr shares

Indicative IPO process time line

Finalization of basis of allotment	11 th Dec. 2025
Unblocking of ASBA account	12 th Dec. 2025
Credit to demat accounts	12 th Dec. 2025
Commencement of trading	15 th Dec. 2025

Pre and post - issue shareholding pattern

	Pre-issue	Post-issue
Promoter & promoter group	72.50%	69.00%
Public	27.50%	31.00%
Non-promoter & Non-public	0.00%	0.00%
Total	100.00%	100.00%

Retail application money at higher cut-off price per lot

Number of shares per lot	14
Employee Discount	Rs. 54
Application money	Rs. 14,868 per lot

Research Analyst: Rajnath Yadav

Email: rajnath.yadav@choiceindia.com

Ph: +91 6707 9999; Ext: 912

Peer Comparison:

Company name	FV (Rs.)	CMP (Rs.)	MCAP (Rs. cr)	EV (Rs.)	6M Return (%)	12M Return (%)	FY25 Revenue (Rs. cr)	FY25 EBITDA (Rs. cr)	FY25 PAT (Rs. cr)	FY25 EBITDA margin (%)	FY25 PAT margin (%)
Corona Remedies Ltd.	10	1,062	6,495	6,555	-	-	1,196	240	149	20.1%	12.5%
Abbott India Ltd	10	28,959	61,536	60,105	-9.0%	-0.3%	6,409	1,695	1,414	26.4%	22.1%
Alkem Laboratories Ltd	2	5,670	67,793	67,611	16.5%	3.1%	12,965	2,512	2,215	19.4%	17.1%
ERIS Lifesciences Ltd	1	1,555	21,182	23,437	-5.2%	6.4%	2,894	1,018	375	35.2%	13.0%
Glaxosmithkline Pharmaceuticals Ltd	10	2,522	42,724	41,330	-25.1%	8.6%	3,749	1,179	928	31.4%	24.8%
J B Chemicals & Pharmaceuticals Ltd	1	1,818	28,479	28,378	8.8%	3.5%	3,918	1,032	660	26.3%	16.8%
Mankind Pharma Ltd	1	2,212	91,312	99,269	-6.4%	-14.7%	12,207	3,026	2,011	24.8%	16.5%
Pfizer Ltd	10	4,972	22,746	19,986	-10.8%	-4.5%	2,281	742	768	32.5%	33.7%
Sanofi India Ltd	10	4,372	10,069	9,793	-30.0%	-30.6%	2,013	491	414	24.4%	20.6%
Torrent Pharmaceuticals Ltd	5	3,785	1,28,102	1,30,725	19.0%	13.6%	11,516	3,721	1,911	32.3%	16.6%
Average										28.1%	20.1%

Company name	4Y top-line growth (CAGR)	4Y EBITDA growth (CAGR)	4Y PAT growth (CAGR)	Average 4Y EBITDA margin	Average 4Y PAT margin	4Y average RoE	4Y average RoCE	Avg 4Y Receivable days	Avg 4Y Inventory Days	Avg 4Y Payable Days	Net Worth
Corona Remedies Ltd.	24.7%	137.9%	-	13.2%	7.7%	16.0%	17.3%	36	38	41	607
Abbott India Ltd	9.2%	15.9%	21.0%	24.0%	19.1%	33.4%	44.7%	20	44	109	4,233
Alkem Laboratories Ltd	6.8%	6.9%	9.7%	17.6%	14.0%	17.8%	18.2%	42	56	124	11,985
ERIS Lifesciences Ltd	29.0%	27.7%	-2.6%	34.3%	21.3%	18.0%	17.2%	51	28	147	2,855
Glaxosmithkline Pharmaceuticals Ltd	4.6%	15.7%	-18.2%	26.4%	28.1%	32.2%	47.5%	21	49	151	1,951
J B Chemicals & Pharmaceuticals Ltd	17.4%	23.9%	19.6%	24.1%	15.4%	20.4%	25.1%	66	49	90	3,434
Mankind Pharma Ltd	16.2%	15.0%	11.4%	24.2%	17.3%	21.5%	26.1%	24	59	116	14,332
Pfizer Ltd	-4.4%	-3.9%	7.8%	31.8%	27.0%	19.9%	26.5%	23	64	99	4,218
Sanofi India Ltd	-12.0%	-13.6%	-24.0%	25.0%	26.3%	37.8%	50.0%	23	74	116	861
Torrent Pharmaceuticals Ltd	10.6%	15.2%	35.0%	30.5%	13.5%	21.4%	21.6%	40	54	277	7,590
Average	8.6%	11.4%	6.6%	26.4%	20.2%	24.7%	30.7%	34	53	136	

Company name	Total Debt	Cash	FY25 RoE (%)	FY25 RoCE (%)	P / E	P/B	EV / Sales	EV / EBITDA	MCAP / Sales	EPS (Rs.)	BVPS (Rs.)	D/E
Corona Remedies Ltd.	178	119	24.6%	27.4%	43.5	10.7	5.5	27.3	5.4	24.4	99.3	0.3
Abbott India Ltd	197	1,628	33.4%	47.9%	43.5	14.5	9.4	35.5	9.6	665.4	1,992.1	0.0
Alkem Laboratories Ltd	1,381	1,563	18.5%	21.6%	30.6	5.7	5.2	26.9	5.2	185.3	1,002.4	0.1
ERIS Lifesciences Ltd	2,478	223	13.1%	13.6%	56.5	7.4	8.1	23.0	7.3	27.5	209.6	0.9
Glaxosmithkline Pharmaceuticals Ltd	10	1,404	47.6%	67.6%	46.0	21.9	11.0	35.1	11.4	54.8	115.2	0.0
J B Chemicals & Pharmaceuticals Ltd	28	129	19.2%	26.7%	43.1	8.3	7.2	27.5	7.3	42.1	219.2	0.0
Mankind Pharma Ltd	8,511	554	14.0%	18.3%	45.4	6.4	8.1	32.8	7.5	48.7	347.2	0.6
Pfizer Ltd	41	2,801	18.2%	26.2%	29.6	5.4	8.8	26.9	10.0	167.9	922.0	0.0
Sanofi India Ltd	19	295	48.1%	46.1%	24.3	11.7	4.9	19.9	5.0	179.8	373.9	0.0
Torrent Pharmaceuticals Ltd	3,202	579	25.2%	27.3%	67.0	16.9	11.4	35.1	11.1	56.5	224.3	0.4
Average			26.4%	32.8%	42.9	10.9	8.2	29.2	8.3			0.2

Note: Considered financials for the period during FY22-25 (with IPO adjustments); Source: Choice Broking Research

Key Highlights of the Industry and the Company:

- The company has a diversified portfolio of 71 brands as of June 30, 2025, catering to multiple therapeutic areas including women's healthcare, cardio-diabeto, pain management, urology, and others. Its core targeted therapy areas—women's healthcare, cardio-diabeto, pain management, and urology—together contributed 68.26% of domestic sales in MAT June 2025 and recorded a strong growth of 22.40% CAGR from MAT June 2022 to MAT June 2025. Within these segments, women's healthcare accounted for 28.56% of domestic sales, followed by cardio-diabeto (comprising cardiovascular and anti-diabetic therapies) at 23.38%, pain management at 11.79%, and urology at 4.53% in MAT June 2025.
- CRL's focused strategy of engaging with specialist and super-specialist doctors has enabled the company to outpace overall prescription growth in IPM during MAT June 2022 to MAT June 2025. This strategy is supported by the targeted deployment of marketing and distribution teams across urban and semi-urban markets, which together contributed 75.11% of domestic sales in MAT June 2025.

Continue:

- Specialists and super-specialists accounted for 75.75% of CRL's prescriptions during MAT June 2025, significantly higher than the IPM average of 60.96%. As a result of this improved market positioning, CRL's industry ranking strengthened from 37th in MAT June 2022 to the 29th largest pharmaceutical company in India by MAT June 2025, as per the RHP.
- CRL operates two manufacturing facilities located in Gujarat and Himachal Pradesh, and is currently commissioning a hormone manufacturing facility in Gujarat, which is expected to commence commercial operations in Q1 FY27. The company's facilities support a wide range of pharmaceutical dosage and packaging forms, including tablets, capsules (both hard and soft gelatin), sachets, liquids, and drops.
- CRL has capabilities to manage complex manufacturing processes at scale, offering advanced delivery systems such as oral, effervescent, controlled-release, modified-release, and bi-layered tablets; hard and soft gelatin capsules; as well as oral powders, liquids, and suspensions. As of June 30, 2025, CRL employed 761 personnel across its manufacturing operations and operates a total of 11 production lines.
- CRL pursues a focused strategy of strategic brand acquisitions and in-licensing arrangements to address therapy gaps in its portfolio and build complementary capabilities such as backward integration, marketing tie-ups, and product diversification. This strategy enables the company to broaden its therapeutic footprint and strengthen its competitive position across key segments.
- During FY24, CRL acquired the Myoril brand from Sanofi, significantly strengthening its pain management portfolio and expanding its presence in this critical therapeutic area. Earlier, the company acquired Vitneurin, Stelbid, Dilo DX, and Dilo BM from GlaxoSmithKline (GSK), reinforcing its position in nutraceuticals, respiratory, and gastroenterology.
- Additionally, the acquisition of Obimet and Thyrocab from Abbott India enhanced CRL's presence in diabetes and thyroid management, while the acquisition of Fostine, Menodac, Ovidac, Vageston, Luprofact, Noklot, and Spye from Bayer Zydus Pharma Private Limited further consolidated its position in women's health and cardio-diabeto therapeutic areas.
- CRL has historically derived a significant majority of its operating revenue from India, with approximately 96% contributed by the domestic market and the remaining 4% from international operations. While India continues to remain the core market, the company is strategically focused on expanding its global presence. This expansion is being driven by its hormone product portfolio, strong R&D capabilities, and differentiated offerings, enabling entry into select international markets. Currently, CRL has a presence across more than 20 countries, including the UAE, Uzbekistan, the Philippines, Kenya, Cyprus, among others.
- CRL derives a significant portion of its domestic sales from the West Zone, comprising Gujarat, Maharashtra, Chhattisgarh, Goa, and Madhya Pradesh, which together accounted for 47.30% of domestic sales in MAT June 2025. The company's revenue is predominantly driven by chronic and sub-chronic therapeutic segments, including women's healthcare, cardio-diabeto, pain management, and VMN. Leading brands such as B-29, Myoril, Tricium, Cortel, and Obimet operate within these segments and contribute approximately 70% of total revenue, while acute therapies account for the remaining 30%.

Revenue bifurcation (Rs. Cr)						
Particulars	FY23 C	FY24 C	FY25 C	3M ended June'30, 2025	CAGR over FY23-25	Annual growth over FY24
Women's Healthcare	259.1	291.5	329.4	97.4	12.7%	13.0%
% of revenue	29.3%	28.7%	27.5%	28.1%		
Cardio-diabeto	182.2	230.4	283.1	87.0	24.7%	22.9%
% of revenue	20.6%	22.7%	23.7%	25.1%		
Pain Management	54.0	90.8	134.1	41.4	57.6%	47.7%
% of revenue	6.1%	8.9%	11.2%	11.9%		
Urology	14.3	21.8	32.8	10.4	51.6%	50.2%
% of revenue	1.6%	2.2%	2.7%	3.0%		
Others	374.5	380.0	417.1	110.4	5.5%	9.7%
% of revenue	42.4%	37.5%	34.9%	31.9%		
Total Revenue	884.1	1,014.5	1,196.4	346.5	16.3%	17.9%

Financial statements:

Restated consolidated profit and loss statement (Rs. cr)							
	FY22 S	FY23 C	FY24 C	FY25 C	3M ended June'30, 2025	CAGR over FY22-25	Annual growth over FY24
Revenue from operations	617.3	884.1	1,014.5	1,196.4	346.5	24.7%	17.9%
Cost of materials consumed	(73.1)	(99.1)	(102.7)	(102.3)	(25.1)	11.9%	-0.4%
Purchase of Stock in trade	(114.1)	(126.4)	(124.9)	(158.0)	(34.8)	11.4%	26.5%
Change in inventories of finished goods and work-in-progress	40.6	14.5	0.8	23.7	(5.9)	-16.4%	-
Gross profit	470.7	673.1	787.6	959.9	280.8	26.8%	21.9%
Employee benefit expenses	(226.7)	(254.8)	(295.4)	(346.1)	(97.4)	15.2%	17.2%
Other expenses	(226.2)	(290.3)	(337.5)	(373.8)	(113.5)	18.2%	10.7%
EBITDA	17.8	128.0	154.7	240.0	69.8	137.9%	55.1%
Depreciation & amortization expenses	(20.5)	(20.1)	(28.3)	(37.2)	(8.9)	22.0%	31.4%
EBIT	(2.7)	107.9	126.5	202.8	60.9	-	60.4%
Finance costs	(4.7)	(4.3)	(14.4)	(10.6)	(2.0)	30.9%	-26.5%
Other income	6.6	7.1	6.5	5.9	2.0	-3.5%	-8.0%
PBT & share of Associate	(0.8)	110.7	118.5	198.1	60.9	-	67.2%
Share of Associate	0.0	0.2	0.0	0.4	(0.2)	-	-
PBT	(0.8)	110.9	118.5	198.5	60.7	-	67.6%
Tax expenses	0.4	(26.0)	(28.0)	(49.1)	(14.5)	-	75.5%
Reported PAT	(0.4)	84.9	90.5	149.4	46.2	-	65.1%

Restated consolidated balance sheet statement (Rs. cr)							
	FY22 S	FY23 C	FY24 C	FY25 C	3M ended June'30, 2025	CAGR over FY22-25	Annual growth over FY24
Equity share capital	51.1	61.2	61.2	61.2	61.2	6.2%	0.0%
Other Equity	269.9	347.4	419.2	545.2	545.9	26.4%	30.0%
Non-current borrowings	16.5	0.0	67.0	16.0	7.0	-1.1%	-76.1%
Lease liabilities	6.8	23.8	22.6	21.0	20.7	45.5%	-7.2%
Other financial liabilities	0.5	0.5	0.0	0.0	0.0	-	-
Non-current provisions	18.8	24.8	32.0	38.6	41.4	27.2%	20.6%
Deferred tax liabilities	0.0	0.0	4.3	8.3	8.2	-	93.5%
Trade payables	84.6	94.4	114.3	143.5	119.0	19.3%	25.6%
Current borrowings	17.2	2.3	67.1	46.7	99.6	39.5%	-30.5%
Current lease liabilities	5.8	1.8	2.2	2.5	2.7	-24.4%	16.4%
Other financial liabilities	13.4	8.0	5.4	4.8	48.0	-29.2%	-12.0%
Other current liabilities	6.5	8.6	6.8	8.4	15.4	8.5%	22.3%
Current Provisions	16.9	18.4	23.5	27.4	28.9	17.6%	16.4%
Current tax liabilities (net)	3.4	3.8	4.8	6.3	14.3	23.2%	31.6%
Total liabilities	511.4	595.0	830.6	929.9	1,012.4	22.1%	12.0%
PP&E	152.2	184.1	191.0	198.7	201.2	9.3%	4.0%
Capital work in progress	14.2	64.7	120.6	186.0	200.4	135.5%	54.2%
Other Intangible assets	9.5	0.5	192.7	171.2	166.0	161.9%	-11.2%
Investments accounted using equity method	0.0	25.5	25.5	25.8	25.6	-	1.5%
Other non-current financial assets	44.5	15.9	3.4	1.4	7.4	-68.5%	-58.7%
Deferred tax asset (net)	3.8	4.3	-	-	-	-	-
Other non-current assets	3.5	8.6	7.5	7.9	2.3	31.5%	5.0%
Inventories	73.9	105.4	98.3	129.5	119.1	20.5%	31.7%
Investments	7.0	6.0	-	-	-	-	-
Trade receivables	74.4	87.0	99.9	118.3	150.9	16.7%	18.4%
Cash & cash equivalents	6.8	14.5	3.2	3.2	2.4	-22.1%	2.1%
Other bank balances	94.2	62.2	66.7	66.1	116.2	-11.1%	-1.0%
Loans	0.4	0.4	0.4	0.4	0.2	-3.8%	0.8%
Other financial assets	0.0	-	-	2.6	10.5	-	-
Other current assets	26.9	16.0	21.4	18.8	10.2	-11.3%	-11.9%
Total assets	511.4	595.0	830.6	929.9	1,012.4	22.1%	12.0%

Restated consolidated cash flow statement (Rs. cr)

	FY22 S	FY23 C	FY24 C	FY25 C	3M ended June'30, 2025	CAGR over FY22-25	Annual growth over FY24
Cash flow before working capital changes	19.5	133.4	165.3	250.8	71.9	134.1%	51.7%
Working capital changes	79.7	(4.9)	9.3	(17.1)	(40.2)	-	-
Cash flow from operating activities	97.7	102.7	156.8	190.5	25.4	24.9%	21.5%
Purchase of PP&E	(34.0)	(94.8)	(286.3)	(91.6)	(12.8)	39.2%	-68.0%
Cash flow from investing activities	(65.8)	(50.2)	(266.6)	(83.8)	(26.4)	8.4%	-68.6%
						-	-
Dividend paid	(7.0)	(7.0)	(16.9)	(22.6)	(40.8)	47.9%	33.6%
Cash flow from financing activities	(29.9)	(44.7)	98.5	(106.6)	0.2	52.8%	-
						-	-
Net cash flow	2.1	7.7	(11.3)	0.1	(0.8)	-68.1%	-
Effect of exchange differences on restatement of foreign currency Cash	(0.0)	(0.0)	0.0	0.0	0.0	-	-
Opening balance of cash	4.8	6.8	14.5	3.2	3.2	-13.0%	-78.2%
Closing balance at the end of the year	6.8	14.5	3.2	3.2	2.4	-22.1%	2.1%

Financial ratios

Particulars	FY22 S	FY23 C	FY24 C	FY25 C	3M ended June'30, 2025	CAGR over FY22- 25	Annual growth over FY24
Profitability ratios							
Revenue growth rate	-	43.2%	14.8%	17.9%		-	318 bps
Gross profit growth rate	-	43.0%	17.0%	21.9%		-	485 bps
Gross profit margin	76.2%	76.1%	77.6%	80.2%	81.0%	399 bps	259 bps
EBITDA growth rate	-	618.2%	20.9%	55.1%		-	3,418 bps
EBITDA margin	2.9%	14.5%	15.3%	20.1%	20.1%	1,717 bps	480 bps
EBIT growth rate	-	-	17.2%	60.4%		-	4,316 bps
EBIT margin	-0.4%	12.2%	12.5%	17.0%	17.6%	1,738 bps	448 bps
Reported PAT growth rate	-	-	6.6%	65.1%		-	5,855 bps
Reported PAT margin	-0.1%	9.6%	8.9%	12.5%	13.3%	1,255 bps	356 bps
Turnover ratios							
Inventory receivable turnover ratio	8.3	9.9	10.0	10.5	2.8	8.0%	5.5%
Trade receivable turnover ratio	8.3	11.0	10.9	11.0	2.6	9.7%	1.0%
Accounts payable turnover ratio	7.3	9.9	9.7	9.3	2.6	8.3%	-4.5%
Fixed asset turnover ratio	3.5	3.5	2.0	2.2	0.6	-15.0%	7.0%
Total asset turnover ratio	1.2	1.5	1.2	1.3	0.3	2.1%	5.3%
Cash Conversion							
Inventories days	44	37	37	35	32	-7.4%	-5.2%
Trade receivables days	44	33	34	33	35	-8.9%	-1.0%
Trade payables days	(50)	(37)	(38)	(39)	(34)	-7.7%	4.8%
Cash conversion cycle	38	33	33	29	33	-8.6%	-12.3%
Liquidity ratios							
Current ratio	1.9	2.1	1.3	1.4	1.2	-9.7%	9.4%
Quick ratio	1.4	1.4	0.9	0.9	0.9	-14.9%	2.3%
Total debt	60.3	36.4	164.4	91.0	178.1	14.7%	-44.6%
Net debt	53.5	22.0	161.2	87.8	175.7	18.0%	-45.6%
Debt to equity	0.2	0.1	0.3	0.2	0.3	-7.2%	-56.1%
Net debt to EBITDA	3.0	0.2	1.0	0.4	2.5	-50.4%	-64.9%
Cash flow ratios							
CFO to PAT	(244.3)	1.2	1.7	1.3	0.5	-	-26.4%
CFO to Capex	2.9	1.1	0.5	2.1	2.0	-10.2%	279.7%
CFO to total debt	1.6	2.8	1.0	2.1	0.1	8.9%	119.5%
CFO to current liabilities	0.7	0.7	0.7	0.8	0.1	6.4%	13.7%
Return ratios							
RoIC (%)	-0.4%	20.5%	16.9%	23.3%	7.1%	2,372 bps	634 bps
RoE (%)	-0.1%	20.8%	18.8%	24.6%	7.6%	2,477 bps	581 bps
RoA (%)	-0.1%	14.3%	10.9%	16.1%	4.6%	1,615 bps	517 bps
RoCE (%)	-0.7%	23.7%	18.7%	27.4%	7.3%	2,805 bps	872 bps
Per Share Data							
Restated adjusted EPS	(0.1)	13.9	14.8	24.4	7.6	-	65.1%
DPS	1.1	1.1	2.8	3.7	6.7	47.9%	33.6%
BVPS	52.5	66.8	78.5	99.1	99.3	23.6%	26.2%
Operating cash flow per share	16.0	16.8	25.6	31.1	4.1	24.9%	21.5%

Source: Choice Equity Broking

IPO rating rationale

Subscribe: An IPO with strong growth prospects and valuation comfort.

Subscribe for Long Term: Relatively better growth prospects but with valuation discomfort.

Avoid: Concerns on both fundamentals and demanded valuation.

Research disclaimer & disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

Choice Equity Broking Pvt. Ltd. ("CEBPL") is a registered Research Analyst Entity (Reg. No. INH000000222; Cin. No. U65999MH2010PTC198714). Registered Address: Sunil Patodia Tower, J B Nagar, Andheri (East), Mumbai 400-099. Tel. No. 022-6707 9999.

Compliance Officer: Prashant Salian; Tel. No. 022-6707-9999; Ext. 2310; email-id: compliance@choiceindia.com

Grievance officer: Deepika Singhvi ; Tel. No. 022-6707-9999; Ext. 834; email-id: ig@choiceindia.com

Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors .

This Research Report (hereinafter referred as "Report") has been prepared by Choice Equity Broking Pvt. Ltd. as a Research Entity (hereinafter referred as "CEBPL RE"). The Research Analysts, strategists are principally responsible for the preparation of "CEBPL RE" research. The research analysts have received compensation based upon various factors, which may include quality of research, investor client feedback, stock picking, competitive factors and firm revenues etc.

Whilst CEBPL has taken all reasonable steps to ensure that this information is correct, CEBPL does not offer any warranty as to the accuracy or completeness of such information. Any person placing reliance on the report to undertake trading does so entirely at his/her own risk and CEBPL does not accept any liability as a result. Securities and derivatives markets may be subject to rapid and unexpected price movements and past performance is not necessarily an indication of future performance.

General disclaimer: This 'Report' is strictly meant for use by the recipient and is not for circulation. This Report does not take into account particular investment objectives, financial situations or specific needs of individual clients nor does it constitute a personal recommendation. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through CEBPL nor any solicitation or offering of any investment/trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein. These information / opinions / views are not meant to serve as a professional investment guide for the readers. No action is solicited based upon the information provided herein. Recipients of this "Report" should rely on information/data arising out of their own study/investigations. It is advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This 'Report' has been prepared on the basis of publicly available information, internally developed data and other sources believed by CEBPL to be reliable. CEBPL or its directors, employees, affiliates or representatives shall not be responsible for, or warrant for the accuracy, completeness, adequacy and reliability of such information / opinions / views. Though due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, affiliates or representatives of CEBPL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information / opinions / views contained in this Report.

The price and value of the investments referred to in this Report and the income from them may tend to go down as well as up, and investors may incur losses on any investments. Yester performance shall not be a guide for future performance. CEBPL does not provide tax advice to its clients, and all investors are strongly advised to take advice of their tax advisers regarding taxation aspects of any potential investment. Opinions are based on the current scenario as of the date appearing on this 'Report' only. CEBPL does not undertake to advise you as to any change of our views expressed in this "Report" may differ on account of differences in research methodology, personal judgment and difference in time horizons for which recommendations are made. User should keep this risk in mind and not hold CEBPL, its employees and associates responsible for any losses, damages of any type whatsoever.

Disclaimers in respect of jurisdiction: This Report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject "CEBPL RE" to any registration or licensing requirement within such jurisdiction(s). No action has been or will be taken by "CEBPL RE" in any jurisdiction (other than India), where any action for such purpose(s) is required. Accordingly, this 'Report' shall not be possessed, circulated and/or distributed in any such country or jurisdiction unless such action is in compliance with all applicable laws and regulations of such country or jurisdiction. "CEBPL" requires such recipient to inform himself about and to observe any restrictions at his own expense, without any liability to "CEBPL". Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in Mumbai (India).

Statements on ownership and material conflicts of interest, compensation - CEBPL and Associates reciprocates to the best of the knowledge and belief of CEBPL/ its Associates/ research Analyst who is preparing this Report.

Disclosures of interest (Additional):

- 1) "CEBPL", its research Analyst(s), or its associates or relatives of the Research Analyst does not have any financial interest in the company (ies) covered in this Report.
- 2) "CEBPL" its research Analyst, or its associates or relatives of the research analyst affiliates collectively do not hold more than one of the securities of the company (ies) covered in this Report as of the end of the month immediately preceding the distribution of the research report.
- 3) "CEBPL", its research analyst, his/her associate, his/her relative, do not have any other material conflict of interest at the time of publication of this Report.
- 4) "CEBPL", its research analyst, and its associates have not received compensation for investment banking or merchant banking or brokerage services or for any other products or services from the company (ies) covered in this Report, in the past twelve months.
- 5) "CEBPL", its research analyst, or its associates have not managed or co-managed in the previous twelve months, a private or public offering of securities for the company (ies) covered in this Report.
- 6) "CEBPL", or its associates have not received compensation or other benefits from the company (ies) covered in this Report or from any third party, in connection with the Report.
- 7) CEBPL research analyst has not served as an Officer, Director, or employee of the company (ies) covered in the Report.
- 8) "CEBPL", its research analyst has not been engaged in market making activity for the company (ies) covered in the Report.

Details of Associates of CEBPL and Brief History of Disciplinary action by regulatory authorities are available on our website i.e. <https://choiceindia.com/research-listing>.

Research disclaimer & disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 (Contd...)

The details of CEBPL, its research analyst and its associates pertaining to the companies covered in the Report are given below:

Sr. no.	Particulars	Yes / No
1.	Whether compensation has been received from the company (ies) covered in the Research report in the past 12 months for investment banking transaction by CEBPL	No
2.	Whether Research Analyst, CEBPL or its associates or relatives of the Research Analyst affiliates collectively hold more than 1% of the company (ies) covered in the Research report	No
3.	Whether compensation has been received by CEBPL or its associates from the company (ies) covered in the Research report	No
4.	CEBPL or its affiliates have managed or co-managed in the previous twelve months a private or public offering of securities for the company (ies) covered in the Research report	No
5.	CEBPL, its research analyst, his associate, or its associates have received compensation for investment banking or merchant banking or brokerage services or for any other products or services from the company (ies) covered in the Research report, in the last twelve months	No

Copyright: The copyright in this research report belongs exclusively to CEBPL. All rights are reserved. Any unauthorized use or disclosure is prohibited. No reprinting or reproduction, in whole or in part, is permitted without the CEBPL's prior consent, except that a recipient may reprint it for internal circulation only and only if it is reprinted in its entirety.

This "Report" is for distribution only under such circumstances as may be permitted by applicable law. This "Report" has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient, even if sent only to a single recipient. This "Report" is not guaranteed to be a complete statement or summary of any securities, markets, reports or developments referred to in this research report. Neither CEBPL nor any of its directors, officers, employees or agents shall have any liability, however arising, for any error, inaccuracy or incompleteness of fact or opinion in this "report" or lack of care in this report's preparation or publication, or any losses or damages which may arise from the use of this research report.

Information barriers may be relied upon by CEBPL, such as "Chinese Walls" to control the flow of information within the areas, units, divisions, groups, or affiliates of CEBPL.

Investing in any non-U.S. securities or related financial instruments (including ADRs) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States. The value of any investment or income from any securities or related financial instruments discussed in this research report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from such securities or related financial instruments.

Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by CEBPL with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior written consent of CEBPL and CEBPL accepts no liability whatsoever for the actions of third parties in this respect.